F. Bosch Et Al. , "Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study," LEUKEMIA , vol.34, no.2, pp.441-450, 2020
Bosch, F. Et Al. 2020. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. LEUKEMIA , vol.34, no.2 , 441-450.
Bosch, F., Cantin, G., Cortelezzi, A., Knauf, W., Tiab, M., Turgut, M., ... Zaritskey, A.(2020). Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. LEUKEMIA , vol.34, no.2, 441-450.
Bosch, Francesc Et Al. "Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study," LEUKEMIA , vol.34, no.2, 441-450, 2020
Bosch, Francesc Et Al. "Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study." LEUKEMIA , vol.34, no.2, pp.441-450, 2020
Bosch, F. Et Al. (2020) . "Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study." LEUKEMIA , vol.34, no.2, pp.441-450.
@article{article, author={Francesc Bosch Et Al. }, title={Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study}, journal={LEUKEMIA}, year=2020, pages={441-450} }